DeepMed Research

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.otsuka-us.com

Clinical Trials

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: aripiprazole IM depot
Drug: aripiprazole tablets

First Posted Date: 2013-06-06

Last Posted Date: 2014-01-22

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 41

Registration Number: NCT01870999

Locations: 🇺🇸
Otsuka Investigative Site, Austin, Texas, United States

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Phase 3

Completed

Conditions: Alzheimer's Disease
Mental Disorder
Agitation Associated With
Alzheimer's Type
Nervous System Diseases

Interventions: Drug: Placebo Oral Tablet
Drug: Brexpiprazole, OPC-34712

First Posted Date: 2013-05-24

Last Posted Date: 2020-12-31

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 433

Registration Number: NCT01862640

A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)

Phase 2

Completed

Conditions: Multidrug Resistant Tuberculosis

Interventions: Drug: Delamanid Pediatric Formulation (DPF)
Drug: Delamanid
Drug: Optimized Background Regimen (OBR)

First Posted Date: 2013-05-22

Last Posted Date: 2020-11-23

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 37

Registration Number: NCT01859923

Locations: 🇵🇭
Lung Center of the Philippines, Quezon City, Metro Manila, Philippines
🇵🇭
De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines
🇿🇦
Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Phase 1

Completed

Conditions: Pediatric
Multidrug Resistant Tuberculosis

Interventions: Drug: 10 mg Delamanid Pediatric Formulation
Drug: 50 mg Delamanid
Drug: 100 mg Delamanid
Drug: 25 mg Pediatric Formulation Delamanid
Drug: 5 mg Delamanid Pediatric Formulation
Drug: Optimized Background Regimen

First Posted Date: 2013-05-17

Last Posted Date: 2018-01-30

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 37

Registration Number: NCT01856634

Locations: 🇵🇭
De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines
🇿🇦
Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa

PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Brexpiprazole 1mg to 4mg

First Posted Date: 2013-05-16

Last Posted Date: 2016-02-04

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 12

Registration Number: NCT01854944

Locations: 🇺🇸
Columbia University, New York, New York, United States

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Phase 3

Completed

Conditions: Depressive Disorder
Mental Disorders
Depressive Disorder, Major
Mood Disorders
Depression

Interventions: Drug: Placebo
Drug: Seroquel XR
Drug: Brexpiprazole

First Posted Date: 2012-11-16

Last Posted Date: 2018-06-08

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 2182

Registration Number: NCT01727726

Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Phase 3

Completed

Conditions: Tourette's Disorder
Tic Disorder

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2012-11-16

Last Posted Date: 2015-02-13

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 133

Registration Number: NCT01727700

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Phase 3

Completed

Conditions: Tic Disorder
Tourette's Disorder

Interventions: Drug: Aripiprazole

First Posted Date: 2012-11-16

Last Posted Date: 2015-10-16

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 110

Registration Number: NCT01727713

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: OPB-111077

First Posted Date: 2012-10-22

Last Posted Date: 2016-04-05

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 145

Registration Number: NCT01711034

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar I

Interventions: Drug: Aripiprazole

First Posted Date: 2012-10-19

Last Posted Date: 2018-09-21

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 748

Registration Number: NCT01710709

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy